Clinical Trials Browser

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

25 enrolled

Genitourinary

Penile Squamous Cell Carcinoma (PSCC)

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06891560 2026-03-20

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Phase 2 Recruiting

34 enrolled

Carcinoma, Adenoid Cystic

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Phase 2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Phase 1/2 Recruiting

41 enrolled

Genitourinary

Advanced Bladder Cancer

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Phase 2 Recruiting

47 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT07221942 2026-02-19

IMPROEV

Phase 2 Recruiting

97 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

47 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Phase 2 Recruiting

24 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04754191 2026-02-12

ENCORE

Phase 2 Active not recruiting

34 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Phase 2 Recruiting

21 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04878029 2026-01-23

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Recruiting

32 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07139977 2026-01-20

EV-4-EC

Phase 2 Not yet recruiting

12 enrolled

Gynecologic

Endometrial Neoplasms

NCT07346053 2026-01-16

Chrono-EVP

Phase 3 Not yet recruiting

224 enrolled

Genitourinary

Advanced Bladder Cancer

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

Phase 2 Recruiting

20 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06104618 2025-12-11

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Phase 2 Recruiting

28 enrolled

Genitourinary

Penile Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06906822 2025-09-18

PlugIN

Phase 2 Recruiting

60 enrolled

Dermatologic

Melanoma

NCT06394570 2025-09-15

STAR-EV

Phase 1/2 Recruiting

19 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06302569 2025-09-09

REPRINT

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05879653 2025-08-29

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Phase 2 Recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06356155 2025-07-29

NEPTUNE

Phase 2 Recruiting

32 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

25 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05915351 2025-04-16

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

Phase 2 Active not recruiting

28 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06204614 2024-01-12

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Unknown

18 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma